Sirs, Individuals using oxycodone for pain relief are prone to drug-drug interactions due to the metabolism of oxycodone via cytochrome (CYP) 3A and 2D6. Recent studies involving healthy subjects show that CYP3A is more significant in the elimination of oxycodone than CYP2D6. The inhibition of hepatic and/or intestinal CYP3A with voriconazole, itraconazole, ketoconazole, human immunodeficiency virus protease inhibitors or grapefruit juice increases exposure to oral oxycodone in healthy subjects and may enhance its analgesic or adverse effects [1] [2] [3] [4] [5] [6] [7] [8] .
In this issue of European Journal of Clinical Pharmacology, Watanabe et al. report the case of a male patient with Burkitt's lymphoma who experienced enhanced analgesic and adverse effects of oxycodone during concomitant treatment of a systemic fungal infection with voriconazole administered intravenously [9] . They also present a retrospective case series of eight other patients with cancer pain who were predisposed to an interaction between oxycodone and voriconazole. Six of these patients experienced drowsiness, vomiting or hypopnea within a few days after starting voriconazole treatment. A number of patients showed a diminished need for additional doses of opioid. In one patient, analgesia was inadequate after the discontinuation of voriconazole. The adverse effects observed in these patients were more typical of opioids than for voriconazole. Based on the pharmacokinetic results of previous interaction studies conducted with healthy subjects, the authors conclude that the observed symptoms were due to increased plasma concentrations of oxycodone caused by CYP3A-mediated inhibition of oxycodone metabolism by voriconazole.
Genetic polymorphism at the CYP2D6 locus has been suggested to influence the pharmacokinetic profile and analgesic effect of oxycodone. Two of the patients in the Watanabe et al. [9] case series did not experience alterations in the effects of oxycodone during voriconazole treatment. In ultrarapid CYP2D6 metabolisers, oxycodone concentrations remain low, even during the concomitant administration of CYP3A inhibitors [1, 5, 6] . It is thus theoretically possible that one or both of these patients were ultrarapid metabolisers of CYP2D6. Similarly, drugs inhibiting CYP2D6 or the poor metaboliser CYP2D6 genotype may partly explain the observed findings in patients with exaggerated opioid effects.
Although interaction studies of opioid analgesics with healthy subjects are useful and provide accurate pharmacokinetic data, there are limitations to such studies, especially in terms of assessing the impact of the interaction on the analgesic effect of the drug. The doses of opioids in studies involving healthy subjects have to be kept substantially lower than what can be seen in clinical practice. On the other hand, experimental pain tests do not always correlate well with clinical pain for a variety of reasons, and the loglinear relationship between drug concentration and effect may further hamper the interpretation of results. Because the main focus of studies conducted with healthy subjects is on the pharmacokinetic interaction, these studies are often underpowered in terms of demonstrating significant differences in pharmacodynamic measurements.
The study of drug-drug interactions is challenging in all clinical patient populations, but especially in those patients who are critically ill or require multiple medications. Patient data from case series of clinical drug-drug interactions, such as those presented by Watanabe et al. [9] , are valuable as they relate directly to the clinical applicability of interaction studies conducted in healthy subjects.
